Astellas Pharma
Astellas Pharma
Community score
moreIncorporated in 2005, Astellas Pharma is a pharmaceutical company with its headquarters in Tokyo, Japan. The company operates in a variety of business segments including Transplantation, Urology, Oncology, Neuroscience, Infectious Diseases, Immunology, Diabetes and Metabolic Diseases, Cardiovascular, and Regenerative Medicine. Astellas Pharma is recognized for key brands such as Prograf (tacrolimus), an immunosuppressant prescribed for organ transplantation; Xtandi (enzalutamide), used in treating prostate cancer; and Vesicare (solifenacin) along with Betanis/Myrbetriq/Betmiga (mirabegron), both of which address overactive bladder conditions. The company's products and services have a broad international reach, being sold in various key markets across the United States, Japan, Europe, Asia, and other global regions, either through direct sales or partnerships. (Powered by AI)
The pharmaceutical industry plays a significant role in disease eradication and improving longevity1. Their R&D into novel cures and treatment tackles a wide range of illnesses and brings innovative new therapies to the global community of patient...
Contamination of rivers, lakes, or other water bodies by chemicals or other microorganisms is considered to be water pollution, which impacts the quality of the water1. According to the U.S. Environmental Protection Agency, "nearly half of the riv...